VKTX – Viking Therapeutics Inc.
VKTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
20.46
Margin Of Safety %
Put/Call OI Ratio
0.2
EPS Next Q Diff
-2
EPS Last/This Y
-1.44
EPS This/Next Y
0.29
Price
34.26
Target Price
94.76
Analyst Recom
1.21
Performance Q
8.49
Upside
-276.8%
Beta
0.68
Ticker: VKTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | VKTX | 38.12 | 0.20 | 0.39 | 200460 |
| 2026-07-14 | VKTX | 37.94 | 0.20 | 0.37 | 203209 |
| 2026-07-15 | VKTX | 37.83 | 0.21 | 0.67 | 203741 |
| 2026-07-16 | VKTX | 36.35 | 0.22 | 0.34 | 207519 |
| 2026-07-17 | VKTX | 37.08 | 0.22 | 0.41 | 211730 |
| 2026-07-20 | VKTX | 36.36 | 0.21 | 0.36 | 181933 |
| 2026-07-21 | VKTX | 37.95 | 0.21 | 0.42 | 186103 |
| 2026-07-22 | VKTX | 37.3 | 0.22 | 0.44 | 190305 |
| 2026-07-23 | VKTX | 35.36 | 0.22 | 0.29 | 192002 |
| 2026-07-24 | VKTX | 34.77 | 0.22 | 0.63 | 195556 |
| 2026-07-27 | VKTX | 34.87 | 0.20 | 0.16 | 186457 |
| 2026-07-28 | VKTX | 33.84 | 0.20 | 0.18 | 191278 |
| 2026-07-29 | VKTX | 33.49 | 0.20 | 0.25 | 196556 |
| 2026-07-30 | VKTX | 33.09 | 0.20 | 0.18 | 200108 |
| 2026-07-31 | VKTX | 31.75 | 0.19 | 0.27 | 206710 |
| 2026-08-03 | VKTX | 32.58 | 0.19 | 0.10 | 200289 |
| 2026-08-04 | VKTX | 32.95 | 0.19 | 0.57 | 209517 |
| 2026-08-05 | VKTX | 33.51 | 0.20 | 0.31 | 217686 |
| 2026-08-06 | VKTX | 33.3 | 0.20 | 0.54 | 222585 |
| 2026-08-07 | VKTX | 34.28 | 0.20 | 0.16 | 225009 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | VKTX | 38.16 | -100.0 | -84.2 | -4.72 |
| 2026-07-14 | VKTX | 37.97 | -100.0 | -94.1 | -4.72 |
| 2026-07-15 | VKTX | 37.84 | -100.0 | -94.6 | -4.72 |
| 2026-07-16 | VKTX | 36.40 | -100.0 | -70.2 | -4.72 |
| 2026-07-17 | VKTX | 37.07 | -100.0 | -110.8 | -4.72 |
| 2026-07-20 | VKTX | 36.38 | -100.0 | -83.5 | -4.72 |
| 2026-07-21 | VKTX | 37.94 | -100.0 | -127.8 | -4.72 |
| 2026-07-22 | VKTX | 37.30 | -100.0 | -84.8 | -4.72 |
| 2026-07-23 | VKTX | 35.38 | -100.0 | -59.8 | -4.72 |
| 2026-07-24 | VKTX | 34.77 | -100.0 | -84.3 | -4.72 |
| 2026-07-27 | VKTX | 34.86 | -100.0 | -98.5 | -4.72 |
| 2026-07-28 | VKTX | 33.84 | -100.0 | -75.6 | -4.72 |
| 2026-07-29 | VKTX | 33.46 | -100.0 | -88.4 | -4.72 |
| 2026-07-30 | VKTX | 33.11 | -100.0 | -90.0 | -4.72 |
| 2026-07-31 | VKTX | 31.74 | -70.4 | -68.6 | -4.60 |
| 2026-08-03 | VKTX | 32.58 | -70.4 | -24.8 | -4.60 |
| 2026-08-04 | VKTX | 32.58 | -70.4 | -24.8 | -4.60 |
| 2026-08-05 | VKTX | 33.53 | -35.0 | -19.1 | -4.64 |
| 2026-08-06 | VKTX | 33.31 | -35.0 | -3.1 | -4.64 |
| 2026-08-07 | VKTX | 34.26 | -32.9 | -26.0 | -4.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | VKTX | 0.14 | 0.38 | 20.83 |
| 2026-07-14 | VKTX | 0.14 | 0.38 | 20.83 |
| 2026-07-15 | VKTX | 0.14 | 0.38 | 20.83 |
| 2026-07-16 | VKTX | 0.14 | 0.38 | 20.83 |
| 2026-07-17 | VKTX | 0.14 | 0.38 | 20.83 |
| 2026-07-20 | VKTX | 0.14 | 0.27 | 20.83 |
| 2026-07-21 | VKTX | 0.14 | 0.27 | 20.83 |
| 2026-07-22 | VKTX | 0.14 | 0.27 | 20.83 |
| 2026-07-23 | VKTX | 0.14 | 0.27 | 20.83 |
| 2026-07-24 | VKTX | 0.14 | 0.27 | 20.83 |
| 2026-07-27 | VKTX | 0.14 | 0.26 | 20.52 |
| 2026-07-28 | VKTX | 0.14 | 0.26 | 20.52 |
| 2026-07-29 | VKTX | 0.14 | 0.26 | 20.52 |
| 2026-07-30 | VKTX | -5.34 | 0.26 | 20.52 |
| 2026-07-31 | VKTX | -5.34 | 0.26 | 20.52 |
| 2026-08-03 | VKTX | -5.32 | -0.00 | 20.43 |
| 2026-08-04 | VKTX | -5.32 | -0.00 | 20.46 |
| 2026-08-05 | VKTX | -5.03 | -0.00 | 20.46 |
| 2026-08-06 | VKTX | -5.03 | -0.00 | 20.46 |
| 2026-08-07 | VKTX | -5.03 | -0.00 | 20.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.89
Avg. EPS Est. Current Quarter
-1.08
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
-5.03
Institutional Transactions
Beta
0.68
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
5
Growth Score
19
Sentiment Score
39
Actual DrawDown %
65.5
Max Drawdown 5-Year %
-78.9
Target Price
94.76
P/E
Forward P/E
PEG
P/S
P/B
9.79
P/Free Cash Flow
EPS
-4.66
Average EPS Est. Cur. Y
-4.63
EPS Next Y. (Est.)
-4.33
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.61
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.1
EBIT Estimation
-26
◆
VKTX
Healthcare
$34.26
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.9
Range 1M
27.4%
Sup Dist
4.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-44.1%
EPS NY
3.8%
52W%
54%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+176.6% upside
Upside
+176.6%
Quality
5
VKTX — P/E HistoricalBiotechnology
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 65
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX
Latest News
—
Caricamento notizie per VKTX…
stock quote shares VKTX – Viking Therapeutics Inc. Stock Price stock today
news today VKTX – Viking Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading